Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Multiple mechanisms have been suggested by
2021-11-03

Multiple mechanisms have been suggested by which glucagon can increase energy expenditure although none have been conclusively proven to be responsible. Both enhanced gluconeogenesis and enhanced protein turnover secondary to hyperglucagonaemia have been suggested as the reason for the increased met
-
Thrilled by these promising results our
2021-11-03

Thrilled by these promising results, our quest for discovering new PPAR-γ/FFAR1 co-agonists was directed towards exploring the other two new scaffolds. So, in this proposed manuscript, we will describe our efforts regarding the synthesis, biological evaluation and molecular docking studies of the be
-
We used a culture model of human erythropoiesis
2021-11-03

We used a culture model of human erythropoiesis that recapitulates all developmental stages [24] to screen a focused set of lncRNAs for potential contribution to this program. We found induction of lncRNA Fas-antisense 1 (Fas-AS1 or Saf) during RBC maturation and demonstrate that essential erythroid
-
To validate that our natural experiment operates primarily
2021-11-03

To validate that our natural experiment operates primarily through a large negative shock to the risk-taking incentives provided by option compensation measured by vega, we do two sets of tests. First, we confirm a significant drop in vega after the adoption of FAS 123R for treated firms relative to
-
Introduction As a compound class histone deacetylase inhibit
2021-11-02

Introduction As a compound class, histone deacetylase inhibitors (HDIs) have been remarkably successful in the treatment of T-cell lymphoma [1]. Vorinostat (suberanilohydroxamic l-ascorbic acid australia or SAHA) was approved by the FDA in 2006 for the treatment of cutaneous T-cell lymphoma [2], [
-
br Conclusion and perspectives Guanylyl cyclases are ubiquit
2021-11-02

Conclusion and perspectives Guanylyl cyclases are ubiquitous enzymes that regulate critical functions in bacteria to humans. In mammals there are seven mGCs and activators of all members have now been identified. Mutations in the genes that encode mGCs or pathologic activation of these enzymes or
-
It is interesting that SEC significantly inhibited cell migr
2021-11-02

It is interesting that SEC significantly inhibited cell migration and EMT in PC3 cells expressing a low RKIP level and HEK293T RKIP−/− cells, while had no effect on HEK293T RKIP+/+ cells. These observations can be interpreted that the RKIP-ANXA7 association may block SEC-induced ANXA7 GTPase activat
-
In addition to the increase of extracellular glutamate ICH c
2021-11-02

In addition to the increase of extracellular glutamate, ICH can also increase the levels of reactive oxygen species (ROS) and oxidative stress. Although the products of red blood cell lysis and plasma components, as well as the excitotoxic effect of glutamate have been to increase oxidative damage (
-
It was previously proposed that glucagon acts in the liver
2021-11-02

It was previously proposed that glucagon acts in the liver, in which a signal is produced and relayed to the dna-pkcs via vagal nerves [8], [36], [37]. The concept that the liver is the primary target site was supported by the studies reporting that the glucagon receptor is localized in the liver b
-
Taken together our results show
2021-11-02

Taken together, our results show that, at least in the in vitro cell line model, methylation within the proximal promoter region of GHSR is an important determinant of its expression; however, to determine whether this represents a physiologically and or pathophysiologically relevant event, further
-
Recent studies suggest that the
2021-11-02

Recent studies suggest that the biological importance of endogenous ghrelin becomes accentuated during exposure to more metabolically-constrained and stressful environments. Indeed, mice lacking either ghrelin or GHSR demonstrate impaired ability to adapt metabolically and/or behaviorally to caloric
-
The Growth Hormone Secretagogue Receptor GHSR also known
2021-11-02

The Growth Hormone Secretagogue Receptor (GHSR), also known as the ghrelin receptor, is a G protein-coupled receptor (GPCR) expressed widely throughout the body and brain, with particular enrichment in src kinase inhibitor regions concerned with homeostatic and motivational function such as the hyp
-
Furthermore our results are the first to demonstrate that
2021-11-02

Furthermore, our results are the first to demonstrate that the stimulating effect of GALP on AVP release in rats is independent of galanin receptors. The same stimulatory GALP influence on AVP secretion has been also observed in the presence of galantide, an antagonist of Gal receptors in the incuba
-
PF-04449913 br Introduction Hepatitis B virus
2021-11-01

Introduction Hepatitis B virus (HBV) infects about 2 billion people worldwide and is a leading cause of liver disease including liver fibrosis, cirrhosis and hepatocellular carcinoma (Trepo et al., 2014). Most current HBV therapies are based on nucleos(t)ide analogs and pegylated interferon alpha
-
br Clinical development of anti NASH
2021-11-01

Clinical development of anti-NASH drug therapies The current understanding of NASH pathogenesis has led to broad efforts to target several features of the disease, alone or in combination, even in the absence of liver-guided therapies. Therefore, drug development in NASH is a rapidly changing fie
16201 records 555/1081 page Previous Next First page 上5页 551552553554555 下5页 Last page